Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/350255
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Effectiveness of fosfomycin trometamol as oral step-down therapy for bacteraemic urinary tract infections due to MDR Escherichia coli: a post hoc analysis of the FOREST randomized trial |
Autor: | Sojo-Dorado, Jesús CSIC; López-Hernández, Inmaculada CSIC; Hernández Torres, Alicia; Retamar Gentil, Pilar CSIC ORCID; Merino de Lucas, Esperanza; Escolà‐Vergé, Laura; Bereciartúa, Elena; García-Vázquez, Elisa; Pintado, Vicente; Boix-Palop, Lucía; Natera Kindelán, Clara; Sorlí, Luisa; Borrell, Nuria; Amador, Concha; Shaw, Evelyn; Jover-Sáenz, Alfredo; Molina, José; Martínez-Álvarez, Rosa M.; Dueñas, Carlos; Calvo-Montes, Jorge; Lecuona, María; Pomar, Virginia; Borreguero, Irene; Palomo, Virginia CSIC; Docobo-Pérez, Fernando CSIC ORCID; Pascual, Álvaro CSIC ORCID; Rodríguez-Baño, Jesús CSIC ORCID; on behalf of CIBERINFEC-GEIRAS-FOREST group | Fecha de publicación: | jul-2023 | Editor: | Oxford University Press | Citación: | Journal of Antimicrobial Chemotherapy 78(7): 1658-1666 (2023) | Resumen: | [Background] Fosfomycin is a potentially attractive option as step-down therapy for bacteraemic urinary tract infections (BUTI), but available data are scarce. Our objective was to compare the effectiveness and safety of fosfomycin trometamol and other oral drugs as step-down therapy in patients with BUTI due to MDR Escherichia coli (MDR-Ec). [Methods] Participants in the FOREST trial (comparing IV fosfomycin with ceftriaxone or meropenem for BUTI caused by MDR-Ec in 22 Spanish hospitals from June 2014 to December 2018) who were stepped-down to oral fosfomycin (3 g q48h) or other drugs were included. The primary endpoint was clinical and microbiological cure (CMC) 5–7 days after finalization of treatment. A multivariate analysis was performed using logistic regression to estimate the association of oral step-down with fosfomycin with CMC adjusted for confounders. [Results] Overall, 61 patients switched to oral fosfomycin trometamol and 47 to other drugs (cefuroxime axetil, 28; amoxicillin/clavulanic acid and trimethoprim/sulfamethoxazole, 7 each; ciprofloxacin, 5) were included. CMC was reached by 48/61 patients (78.7%) treated with fosfomycin trometamol and 38/47 (80.9%) with other drugs (difference, −2.2; 95% CI: −17.5 to 13.1; P = 0.38). Subgroup analyses provided similar results. Relapses occurred in 9/61 (15.0%) and 2/47 (4.3%) of patients, respectively (P = 0.03). The adjusted OR for CMC was 1.11 (95% CI: 0.42–3.29, P = 0.75). No relevant differences in adverse events were seen. [Conclusions] Fosfomycin trometamol might be a reasonable option as step-down therapy in patients with BUTI due to MDR-Ec but the higher rate of relapses would need further assessment. |
Descripción: | © The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. | Versión del editor: | https://doi.org/10.1093/jac/dkad147 | URI: | http://hdl.handle.net/10261/350255 | DOI: | 10.1093/jac/dkad147 | ISSN: | 0305-7453 | E-ISSN: | 1460-2091 |
Aparece en las colecciones: | (IBIS) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Effectiveness_JAC_2023_OA.pdf | 347,37 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
1
checked on 08-abr-2024
Page view(s)
14
checked on 28-abr-2024
Download(s)
7
checked on 28-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Este item está licenciado bajo una Licencia Creative Commons